Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Maintains Overweight on Synaptics, Raises Price Target to $160

Keybanc Maintains Overweight on Synaptics, Raises Price Target to $160

Keybanc analyst John Vinh maintains Synaptics (NASDAQ:SYNA) with a Overweight and raises the price target from $115 to $160.

byBenzinga Newsdesk

February 3, 2023

1 minute read

Keybanc analyst John Vinh maintains Synaptics (NASDAQ:SYNA) with a Overweight and raises the price target from $115 to $160.

News

Medtronic Granted U.S. Patent #1559626: Means To Treat Alzheimer’s Disease Via Flushing Of Brain Parenchyma

By Charles Gross

January 24, 7:40 AM

https://www.scribd.com/document/621584898/MDT-Patent

MDT

Louisiana-Pacific Q3 Results Exceed Street Expectation; CEO Says ‘We Believe Siding Inventories Have Normalized’

By Akanksha Bakshi

November 1, 11:58 AM

Louisiana-Pacific Corp (NYSE: LPX) reported

LPX

Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate – A Setback in High-Risk Melanoma Treatment

By Vandana Singh

May 13, 11:09 AM

Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events.

MRK

News

California Governor Gavin Newsom Tweeted Earlier: California Won’t Be Doing Businessv With @walgreens –Or Any Company That Cowers To The Extremists And Puts Women’s Lives At Risk

By Charles Gross

March 6, 2:50 PM

https://twitter.com/GavinNewsom/status/1632811406344192000?s=20

WBA

Keybanc Maintains Overweight on Synaptics, Raises Price Target to $160

Related Posts

Medtronic Granted U.S. Patent #1559626: Means To Treat Alzheimer’s Disease Via Flushing Of Brain Parenchyma

Louisiana-Pacific Q3 Results Exceed Street Expectation; CEO Says ‘We Believe Siding Inventories Have Normalized’

Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate – A Setback in High-Risk Melanoma Treatment

California Governor Gavin Newsom Tweeted Earlier: California Won’t Be Doing Businessv With @walgreens –Or Any Company That Cowers To The Extremists And Puts Women’s Lives At Risk